Inhibition of salivary glands to reduce uptake and toxicity of PSMA-ligands
Phase 2
Completed
- Conditions
- accumulation in salivary glands.Biodistribution of PSMA-ligands10039404
- Registration Number
- NL-OMON46014
- Lead Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
- Received PSMA PET/CT on clinical indication (<1 month before study date).
- At least one PSMA-positive tumour location visible with diameter >1cm.
Exclusion Criteria
- Poor quality of the baseline PSMA PET/CT scan
- Planned start or changes in treatment prior to study procedures.
- Age < 18y
- Inability to provide informed consent
- History of disease or treatment involving the salivary glands
- Currently on neurotransmitter blocking/stimulating medication
- Contra-indications for anticholinergic medication, including glaucoma, obstruction of digestive or urological tract, megacolon, ileus, tardive dyskinesia
- (For optional MR-scans only): Standard contra-indications for MR
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The total uptake of Ga-PSMA on PET/CT in all macroscopic salivary glands<br /><br>together (and its relative decrease after inhibition with GPB). </p><br>
- Secondary Outcome Measures
Name Time Method <p>The total perfusion signal on ASL MR in representative thick slices of the<br /><br>parotid and submandibular glands together (and its relative decrease after<br /><br>inhibition with GPB).</p><br>